技术资料
-
Dowling RJO et al. ( 2012) Journal of molecular endocrinology 48 3 R31--43Metformin in cancer: translational challenges.
The anti-diabetic drug metformin is rapidly emerging as a potential anti-cancer agent. Metformin,effective in treating type 2 diabetes and the insulin resistance syndromes,improves insulin resistance by reducing hepatic gluconeogenesis and by enhancing glucose uptake by skeletal muscle. Epidemiological studies have consistently associated metformin use with decreased cancer incidence and cancer-related mortality. Furthermore,numerous preclinical and clinical studies have demonstrated anti-cancer effects of metformin,leading to an explosion of interest in evaluating this agent in human cancer. The effects of metformin on circulating insulin levels indicate a potential efficacy towards cancers associated with hyperinsulinaemia; however,metformin may also directly inhibit tumour growth. In this review,we describe the mechanism of action of metformin and summarise the epidemiological,clinical and preclinical evidence supporting a role for metformin in the treatment of cancer. In addition,the challenges associated with translating preclinical results into therapeutic benefit in the clinical setting will be discussed. View Publication -
Koivunen P et al. (MAR 2012) Nature 483 7390 484--8Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.
The identification of succinate dehydrogenase (SDH),fumarate hydratase (FH) and isocitrate dehydrogenase (IDH) mutations in human cancers has rekindled the idea that altered cellular metabolism can transform cells. Inactivating SDH and FH mutations cause the accumulation of succinate and fumarate,respectively,which can inhibit 2-oxoglutarate (2-OG)-dependent enzymes,including the EGLN prolyl 4-hydroxylases that mark the hypoxia inducible factor (HIF) transcription factor for polyubiquitylation and proteasomal degradation. Inappropriate HIF activation is suspected of contributing to the pathogenesis of SDH-defective and FH-defective tumours but can suppress tumour growth in some other contexts. IDH1 and IDH2,which catalyse the interconversion of isocitrate and 2-OG,are frequently mutated in human brain tumours and leukaemias. The resulting mutants have the neomorphic ability to convert 2-OG to the (R)-enantiomer of 2-hydroxyglutarate ((R)-2HG). Here we show that (R)-2HG,but not (S)-2HG,stimulates EGLN activity,leading to diminished HIF levels,which enhances the proliferation and soft agar growth of human astrocytes. These findings define an enantiomer-specific mechanism by which the (R)-2HG that accumulates in IDH mutant brain tumours promotes transformation and provide a justification for exploring EGLN inhibition as a potential treatment strategy. View Publication -
Borgegard T et al. (APR 2012) The Journal of biological chemistry 287 15 11810--9First and second generation γ-secretase modulators (GSMs) modulate amyloid-β (Aβ) peptide production through different mechanisms.
γ-Secretase-mediated cleavage of amyloid precursor protein (APP) results in the production of Alzheimer disease-related amyloid-β (Aβ) peptides. The Aβ42 peptide in particular plays a pivotal role in Alzheimer disease pathogenesis and represents a major drug target. Several γ-secretase modulators (GSMs),such as the nonsteroidal anti-inflammatory drugs (R)-flurbiprofen and sulindac sulfide,have been suggested to modulate the Alzheimer-related Aβ production by targeting the APP. Here,we describe novel GSMs that are selective for Aβ modulation and do not impair processing of Notch,EphB2,or EphA4. The GSMs modulate Aβ both in cell and cell-free systems as well as lower amyloidogenic Aβ42 levels in the mouse brain. Both radioligand binding and cellular cross-competition experiments reveal a competitive relationship between the AstraZeneca (AZ) GSMs and the established second generation GSM,E2012,but a noncompetitive interaction between AZ GSMs and the first generation GSMs (R)-flurbiprofen and sulindac sulfide. The binding of a (3)H-labeled AZ GSM analog does not co-localize with APP but overlaps anatomically with a γ-secretase targeting inhibitor in rodent brains. Combined,these data provide compelling evidence of a growing class of in vivo active GSMs,which are selective for Aβ modulation and have a different mechanism of action compared with the original class of GSMs described. View Publication -
Szerlip NJ et al. (FEB 2012) Proceedings of the National Academy of Sciences of the United States of America 109 8 3041--6Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.
Glioblastoma (GBM) is distinguished by a high degree of intratumoral heterogeneity,which extends to the pattern of expression and amplification of receptor tyrosine kinases (RTKs). Although most GBMs harbor RTK amplifications,clinical trials of small-molecule inhibitors targeting individual RTKs have been disappointing to date. Activation of multiple RTKs within individual GBMs provides a theoretical mechanism of resistance; however,the spectrum of functional RTK dependence among tumor cell subpopulations in actual tumors is unknown. We investigated the pattern of heterogeneity of RTK amplification and functional RTK dependence in GBM tumor cell subpopulations. Analysis of The Cancer Genome Atlas GBM dataset identified 34 of 463 cases showing independent focal amplification of two or more RTKs,most commonly platelet-derived growth factor receptor α (PDGFRA) and epidermal growth factor receptor (EGFR). Dual-color fluorescence in situ hybridization was performed on eight samples with EGFR and PDGFRA amplification,revealing distinct tumor cell subpopulations amplified for only one RTK; in all cases these predominated over cells amplified for both. Cell lines derived from coamplified tumors exhibited genotype selection under RTK-targeted ligand stimulation or pharmacologic inhibition in vitro. Simultaneous inhibition of both EGFR and PDGFR was necessary for abrogation of PI3 kinase pathway activity in the mixed population. DNA sequencing of isolated subpopulations establishes a common clonal origin consistent with late or ongoing divergence of RTK genotype. This phenomenon is especially common among tumors with PDGFRA amplification: overall,43% of PDGFRA-amplified GBM were found to have amplification of EGFR or the hepatocyte growth factor receptor gene (MET) as well. View Publication -
Nicoud IB et al. (SEP 2012) Transfusion 52 9 2055--62Cryopreservation of umbilical cord blood with a novel freezing solution that mimics intracellular ionic composition.
BACKGROUND Cryopreservation protocols have remained relatively unchanged since the first umbilical cord blood banking program was established. This study evaluated the preservation efficacy of a novel intracellular-like cryopreservation solution (CryoStor,BioLife Solutions,Inc.),the rate of addition of two cryopreservation solutions to cord blood units (CBUs),and reduced final dimethyl sulfoxide (DMSO) concentration of 5%. STUDY DESIGN AND METHODS Split-sample CBUs were cryopreserved with either an in-house 20% DMSO-based cryopreservation solution or CryoStor CS10 at a rate of 1 mL/min (n = 10; i.e.,slow addition) or as a bolus injection (n = 6; i.e.,fast addition). Infrared images of exothermic effects of the cryopreservation solutions were monitored relative to the rate of addition. Prefreeze and postthaw colony-forming unit assays,total nucleated cells,and CD34+ cell counts were compared. RESULTS Maximum temperature excursions observed were less than 6°C,regardless of the rate of solution addition. Fast addition resulted in peak excursions approximately twice that of slow addition but the magnitude and duration were minimal and transient. Slow addition of CryoStor CS10 (i.e.,final concentration % 5% DMSO) resulted in significantly better postthaw CD34+ cell recoveries; no other metrics were significantly different. Fast addition of CryoStor resulted in similar postthaw metrics compared to slow addition of the in-house solution. CONCLUSION Slow and fast addition of cryopreservation solutions result in mean temperature changes of approximately 3.3 to 4.45°C. Postthaw recoveries with CryoStor were equivalent to or slightly better than with the in-house cryopreservation solution. CryoStor also provides several advantages including reduced processing time,formulation consistency,and reduced DMSO in the frozen product (% 5%). View Publication -
Ohmine S et al. (JAN 2012) Aging 4 1 60--73Reprogrammed keratinocytes from elderly type 2 diabetes patients suppress senescence genes to acquire induced pluripotency
Nuclear reprogramming enables patient-specific derivation of induced pluripotent stem (iPS) cells from adult tissue. Yet,iPS generation from patients with type 2 diabetes (T2D) has not been demonstrated. Here,we report reproducible iPS derivation of epidermal keratinocytes (HK) from elderly T2D patients. Transduced with human OCT4,SOX2,KLF4 and c-MYC stemness factors under serum-free and feeder-free conditions,reprogrammed cells underwent dedifferentiation with mitochondrial restructuring,induction of endogenous pluripotency genes - including NANOG,LIN28,and TERT,and down-regulation of cytoskeletal,MHC class I- and apoptosis-related genes. Notably,derived iPS clones acquired a rejuvenated state,characterized by elongated telomeres and suppressed senescence-related p15INK4b/p16INK4a gene expression and oxidative stress signaling. Stepwise guidance with lineage-specifying factors,including Indolactam V and GLP-1,redifferentiated HK-derived iPS clones into insulin-producing islet-like progeny. Thus,in elderly T2D patients,reprogramming of keratinocytes ensures a senescence-privileged status yielding iPS cells proficient for regenerative applications. View Publication -
Guan X et al. (MAY 2012) Stem Cell Research 8 3 410--5Derivation of human embryonic stem cells with NEMO deficiency.
Deficiency of the nuclear factor-kappa-B essential modulator (NEMO) is a rare X-linked disorder that presents in boys as hypohydrotic ectodermal dysplasia with immunodeficiency due to defective nuclear factor-κB activation. Here we report on the generation of 2 human embryonic stem cell lines from discarded in vitro fertilization (IVF) embryos ascertained via preimplantation genetic diagnosis. We have derived two human embryonic stem cell lines that carry a T458G hypomorphic mutation in exon 4 of the NEMO (or IKBKG) gene. One of the lines is diploid male; the other is diploid female but has clonally inactivated the X-chromosome that harbors the wild-type IKBKG gene. We show that both lines are pluripotent,have the capacity to differentiate into hematopoietic progenitors,and have defective inhibitor of nuclear factor kappa-B kinase activity. These NEMO deficiency hES cell lines provide an unlimited source for differentiated cell types and may serve as a unique tool to study NEMO deficiency and potentially lead to the development of new therapies for this disease. View Publication -
Li M et al. (AUG 2012) Cancer immunology,immunotherapy : CII 61 8 1255--1268Sensitivity of a novel model of mammary cancer stem cell-like cells to TNF-related death pathways.
Cancer stem cells (CSC) are resistant to radiation and chemotherapy and play a significant role in cancer recurrence and metastatic disease. It is therefore important to identify alternative strategies,such as immunotherapies that can be used to control this refractory population. A CD44(+)CD24(-/low) subpopulation of cells within the B6 PyMT-MMTV transgenic mouse-derived AT-3 mammary carcinoma cell line was identified,which had CSC-like characteristics,including pluripotency and a resistance to chemo- and radiotherapy. Therefore,unlike xenograph models that require immunocompromised settings,this novel system may provide a means to study immune-mediated responses against CSC-like cells. The immunobiology of the AT-3 CSC-like cell population was studied by their surface molecule expression profile and their sensitivity to specified cell death pathways. Comparable levels of Rae-1,CD155,CD54 and higher levels of Fas and DR5 were expressed on the AT-3 CSC-like cells compared to non-CSC-like tumor cells. Expression correlated with an in vitro sensitivity to cell death by NK cells or through the ligation of the death receptors (Fas or DR5),by their ligands or anti-Fas and anti-DR5 mAbs. Indeed,compared to the rest of the AT-3 tumor cells,the CD44(+)CD24(-/low) subpopulation of cells were more sensitive to both Fas- and TRAIL-mediated cell death pathways. Therefore,despite the refractory nature of CSC to other conventional therapies,these CSC-like cells were not inherently resistant to specified forms of immune-mediated cell death. These results encourage the continued investigation into immunotherapeutic strategies as a means of controlling breast CSC,particularly through their cell death pathways. View Publication -
Lee Y et al. (MAR 2012) The EMBO journal 31 5 1177--89ATR maintains select progenitors during nervous system development.
The ATR (ATM (ataxia telangiectasia mutated) and rad3-related) checkpoint kinase is considered critical for signalling DNA replication stress and its dysfunction can lead to the neurodevelopmental disorder,ATR-Seckel syndrome. To understand how ATR functions during neurogenesis,we conditionally deleted Atr broadly throughout the murine nervous system,or in a restricted manner in the dorsal telencephalon. Unexpectedly,in both scenarios,Atr loss impacted neurogenesis relatively late during neural development involving only certain progenitor populations. Whereas the Atr-deficient embryonic cerebellar external germinal layer underwent p53- (and p16(Ink4a/Arf))-independent proliferation arrest,other brain regions suffered apoptosis that was partially p53 dependent. In contrast to other organs,in the nervous system,p53 loss did not worsen the outcome of Atr inactivation. Coincident inactivation of Atm also did not affect the phenotype after Atr deletion,supporting non-overlapping physiological roles for these related DNA damage-response kinases in the brain. Rather than an essential general role in preventing replication stress,our data indicate that ATR functions to monitor genomic integrity in a selective spatiotemporal manner during neurogenesis. View Publication -
Fong H et al. (MAR 2012) Stem cell research 8 2 206--14Transcriptional regulation of TRKC by SOX2 in human embryonic stem cells.
Human embryonic stem (hES) cells have the dual ability to self-renew and differentiate into specialized cell types. However,in order to realize the full potential of these cells it is important to understand how the genes responsible for their unique characteristics are regulated. In this study we examine the regulation of the tropomyosin-related kinase (TRK) genes which encode for receptors important in hES cell survival and self-renewal. Although the TRK genes have been studied in many neuronal cell types,the regulation of these genes in hES cells is unclear. Our study demonstrates a novel regulatory relationship between the TRKC gene and the transcription factor SOX2. Our results found that hES cells highly express full-length and truncated forms of the TRKC gene. However,examination of the related TRKB gene showed a lower overall expression of both full-length and truncated forms. Through RNA interference,we knocked down expression levels of SOX2 in hES cells and examined the expression of TRKC,as well as TRKB. Upon loss of SOX2 we found that TRKC mRNA levels were significantly downregulated but TRKB levels remained unchanged,demonstrating an important regulatory dependence on SOX2 by TRKC. We also found that TRKC protein levels were also decreased after SOX2 knock down. Further analysis found the regulatory region of TRKC to be highly conserved among many mammals with potential SOX binding motifs. We confirmed a specific binding motif as a site that SOX2 utilizes to directly interact with the TRKC regulatory region. In addition,we found that SOX2 drives expression of the TRKC gene by activating a luciferase reporter construct containing the TRKC regulatory region and the SOX binding motif. View Publication -
Funk WD et al. (MAR 2012) Stem Cell Research 8 2 154--64Evaluating the genomic and sequence integrity of human ES cell lines; comparison to normal genomes
Copy number variation (CNV) is a common chromosomal alteration that can occur during in vitro cultivation of human cells and can be accompanied by the accumulation of mutations in coding region sequences. We describe here a systematic application of current molecular technologies to provide a detailed understanding of genomic and sequence profiles of human embryonic stem cell (hESC) lines that were derived under GMP-compliant conditions. We first examined the overall chromosomal integrity using cytogenetic techniques to determine chromosome count,and to detect the presence of cytogenetically aberrant cells in the culture (mosaicism). Assays of copy number variation,using both microarray and sequence-based analyses,provide a detailed view genomic variation in these lines and shows that in early passage cultures of these lines,the size range and distribution of CNVs are entirely consistent with those seen in the genomes of normal individuals. Similarly,genome sequencing shows variation within these lines that is completely within the range seen in normal genomes. Important gene classes,such as tumor suppressors and genetic disease genes,do not display overtly disruptive mutations that could affect the overall safety of cell-based therapeutics. Complete sequence also allows the analysis of important transplantation antigens,such as ABO and HLA types. The combined application of cytogenetic and molecular technologies provides a detailed understanding of genomic and sequence profiles of GMP produced ES lines for potential use as therapeutic agents. View Publication -
Barrett LE et al. (JAN 2012) Cancer cell 21 1 11--24Self-renewal does not predict tumor growth potential in mouse models of high-grade glioma.
Within high-grade gliomas,the precise identities and functional roles of stem-like cells remain unclear. In the normal neurogenic niche,ID (Inhibitor of DNA-binding) genes maintain self-renewal and multipotency of adult neural stem cells. Using PDGF- and KRAS-driven murine models of gliomagenesis,we show that high Id1 expression (Id1(high)) identifies tumor cells with high self-renewal capacity,while low Id1 expression (Id1(low)) identifies tumor cells with proliferative potential but limited self-renewal capacity. Surprisingly,Id1(low) cells generate tumors more rapidly and with higher penetrance than Id1(high) cells. Further,eliminating tumor cell self-renewal through deletion of Id1 has modest effects on animal survival,while knockdown of Olig2 within Id1(low) cells has a significant survival benefit,underscoring the importance of non-self-renewing lineages in disease progression. View Publication
过滤器
筛选结果
产品类型
- 仪器及软件
Show More
Show Less
研究领域
- HIV 70 项目
- HLA 52 项目
- 上皮细胞生物学 269 项目
- 免疫 1012 项目
- 内皮细胞研究 1 项目
- 呼吸系统研究 48 项目
- 嵌合体 25 项目
- 干细胞生物学 2827 项目
- 感染性疾病(传染病) 7 项目
- 抗体制备 7 项目
- 新陈代谢 7 项目
- 杂交瘤制备 2 项目
- 疾病建模 248 项目
- 癌症 6 项目
- 神经科学 650 项目
- 移植研究 100 项目
- 类器官 178 项目
- 细胞外囊泡研究 10 项目
- 细胞治疗开发 18 项目
- 细胞疗法开发 113 项目
- 细胞系制备 191 项目
- 脐带血库 64 项目
- 血管生成细胞研究 1 项目
- 传染病 64 项目
- 内皮细胞生物学 7 项目
- 杂交瘤生成 14 项目
- 癌症研究 724 项目
- 血管生成细胞研究 51 项目
Show More
Show Less
产品系列
- ALDECOUNT 14 项目
- CellPore 11 项目
- CellShield 1 项目
- CellSTACK 1 项目
- DermaCult 1 项目
- EasyPick 1 项目
- ELISA 3 项目
- ES-Cult 78 项目
- Falcon 1 项目
- GloCell 1 项目
- GyneCult 1 项目
- HetaSep 1 项目
- Maestro 2 项目
- Matrigel 2 项目
- MegaCult 37 项目
- STEMprep 11 项目
- ALDEFLUOR 237 项目
- AggreWell 82 项目
- ArciTect 38 项目
- BloodStor 2 项目
- BrainPhys 84 项目
- CellAdhere 3 项目
- ClonaCell 107 项目
- CloneR 9 项目
- CryoStor 75 项目
- EC-Cult 1 项目
- EasySep 963 项目
- EpiCult 15 项目
- HemaTox 4 项目
- HepatiCult 32 项目
- Hypothermosol 1 项目
- ImmunoCult 39 项目
- IntestiCult 213 项目
- Lymphoprep 12 项目
- MammoCult 45 项目
- MesenCult 164 项目
- MethoCult 499 项目
- MyeloCult 65 项目
- MyoCult 10 项目
- NaïveCult 1 项目
- NeuroCult 373 项目
- NeuroFluor 3 项目
- PBS-MINI 8 项目
- PancreaCult 11 项目
- PneumaCult 119 项目
- RSeT 13 项目
- ReLeSR 10 项目
- RoboSep 43 项目
- RosetteSep 268 项目
- STEMdiff 193 项目
- STEMscript 1 项目
- STEMvision 7 项目
- SepMate 38 项目
- SmartDish 1 项目
- StemSpan 251 项目
- TeSR 1545 项目
- ThawSTAR 5 项目
- mFreSR 9 项目
- Highway1 7 项目
Show More
Show Less
细胞类型
- B 细胞 229 项目
- CD4+ 46 项目
- CD8+ 29 项目
- CHO细胞 15 项目
- HEK-293细胞(人胚肾293细胞) 2 项目
- NK 细胞 162 项目
- PSC衍生 37 项目
- T 细胞 441 项目
- 上皮细胞 143 项目
- 中胚层 5 项目
- 乳腺细胞 95 项目
- 先天性淋巴细胞 32 项目
- 全血 10 项目
- 其他子集 1 项目
- 其他细胞系 10 项目
- 内皮细胞 11 项目
- 内胚层 4 项目
- 前列腺细胞 18 项目
- 单个核细胞 93 项目
- 单核细胞 178 项目
- 多能干细胞 1986 项目
- 小胶质细胞 13 项目
- 巨噬细胞 42 项目
- 巨核细胞 10 项目
- 心肌细胞 21 项目
- 成骨细胞 10 项目
- 星形胶质细胞 14 项目
- 杂交瘤细胞 92 项目
- 树突状细胞(DCs) 118 项目
- 气道细胞 4 项目
- 淋巴细胞 73 项目
- 癌细胞及细胞系 149 项目
- 癌细胞和细胞系 1 项目
- 白细胞 24 项目
- 白细胞单采样本 13 项目
- 白血病/淋巴瘤细胞 14 项目
- 监管 1 项目
- 真皮细胞 3 项目
- 神经元 1 项目
- 神经干/祖细胞 465 项目
- 神经细胞 12 项目
- 粒细胞及其亚群 96 项目
- 红系细胞 12 项目
- 红细胞 13 项目
- 肌源干/祖细胞 11 项目
- 肝细胞 40 项目
- 肠道细胞 103 项目
- 肾细胞 4 项目
- 肿瘤细胞 27 项目
- 胰腺细胞 17 项目
- 脂肪细胞 6 项目
- 脑肿瘤干细胞 103 项目
- 血小板 4 项目
- 血浆 3 项目
- 血管生成细胞 1 项目
- 角质形成细胞 1 项目
- 调节性细胞 10 项目
- 软骨细胞 9 项目
- 造血干/祖细胞 968 项目
- 造血干祖细胞 6 项目
- 造血细胞 4 项目
- 间充质基质细胞 25 项目
- 间充质干/祖细胞 188 项目
- 间充质干祖细胞 1 项目
- 间充质细胞 3 项目
- 骨髓基质细胞 1 项目
- 骨髓间质细胞 2 项目
- 髓系细胞 135 项目
- 肾脏细胞 8 项目
- CD4+T细胞 100 项目
- CD8+T细胞 86 项目
- PSC衍生上皮细胞 39 项目
- PSC衍生中胚层 25 项目
- PSC衍生内皮细胞 20 项目
- PSC衍生内胚层 28 项目
- PSC衍生心肌细胞 26 项目
- PSC衍生神经细胞 130 项目
- PSC衍生肝细胞 18 项目
- PSC衍生造血干细胞 39 项目
- PSC衍生间充质细胞 27 项目
- 其他T细胞亚型 31 项目
- 呼吸道细胞 96 项目
- 多巴胺能神经元 6 项目
- 小鼠胚胎成纤维细胞 1 项目
- 浆细胞 17 项目
- 神经元 201 项目
- 调节性T细胞 59 项目
- 骨髓瘤 5 项目
Show More
Show Less

EasySep™小鼠TIL(CD45)正选试剂盒



沪公网安备31010102008431号